IMMUTEP Ltd (IMMP) stock
Close on Nov 12, 2026Market cap $26.93MP/E –Yield –
IMMUTEP Ltd grew revenue 133.9% to A$24.17M over fiscal 2026. Free cash flow was -A$55.56M. At the latest close the market valued the company at A$39.17M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026
Valuation
- Market cap
- A$39.17M
- P/E ratio
- –
- Price to sales
- 1.62
- Price to book
- 0.64
- Dividend yield
- –
- Free cash flow yield
- -141.82%
Fundamentals
- Revenue
- A$24.17M
- Net income
- -A$79.30M
- EPS, diluted
- -0.05 AUD
- Free cash flow
- -A$55.56M
Trading
- Previous close
- $3.56
- Open
- $3.30
- Day's range
- $3.30 – $3.95
- Volume
- 61,541
- Average volume (20 days)
- 28,253
- Beta (5 years)
- 1.68
- RSI (14 days)
- 48.2
- Volatility (1 year)
- 132.7%
- Relative volume
- 3.38×
- WACC
- 13.3%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMMP | S&P 500 | Difference | IMMP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.4% | -2.7% | +2.3 pts | ||
| 3 months | -52.3% | -1.7% | −50.6 pts | ||
| Year to date | -93.6% | +11.9% | −105.5 pts | ||
| 1 year | -89.8% | +12.0% | −101.8 pts | ||
| 3 years | -89.7% | +78.2% | −167.9 pts | -53.2% | +21.2% |
| 5 years | -95.7% | +73.2% | −169.0 pts | -46.8% | +11.6% |
| 10 years | -93.3% | +309.6% | −402.9 pts | -23.7% | +15.1% |
Twelve years at a glance
Fiscal years 2015 to 2026, AUD
Revenue
Net income
EPS, diluted
Free cash flow
Press releases
Releases Immutep filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Immutep
Pharmaceutical Preparations
Immutep is an enterprise involved in clinical research and development activities. The group contracts with external vendors and specialized research organizations to conduct clinical trials and manufacturing operations. It maintains intellectual property assets, including patents and licensing agreements, while administering share-based incentive programs for its personnel and directors.
Company profile, executives and historyImmutep stock: common questions
What is Immutep's stock price?
IMMP closed at $3.65 on Nov 12, 2026, up 2.67% on the day.
What is Immutep's market cap?
Immutep was worth $26.93M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IMMP's P/E ratio?
Immutep lost money over fiscal 2026 (diluted EPS -0.05 AUD), so it has no meaningful P/E ratio.
How much revenue does Immutep make?
Immutep reported revenue of A$24.17M for fiscal 2026, up 133.9% from a year earlier.
Does Immutep pay a dividend?
No. Immutep has not paid a cash dividend over the last twelve months.
How has IMMP stock performed over the past year?
Including dividends, IMMP returned -89.8% over the past year, against +12.0% for the S&P 500.
Who are Immutep's competitors?
Companies most similar to Immutep by business, industry and size include CUE, NAMS, JAGX, ZNTL, HYFT.
See a number that looks wrong?